Viral Arrays for Biodefense

用于生物防御的病毒阵列

• 批准号: 7134485
• 负责人: W. Ian Lipkin
• 金额: $ 99.66万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-01 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7134485
• 关键词: bioinformatics; bioterrorism /chemical warfare; clinical research; human; infection; influenza; information systems; public health; tissue /cell culture

DESCRIPTION (provided by applicant): The objective of this program is to establish stable and sensitive viral microarray assays for public health laboratory, hospital-based clinical laboratory and point-of-care-use to enable differential diagnosis of infection by select NIAID priority agents, agents that may cause signs and symptoms that may mimic those due to infection with select agents, and influenza viruses. We propose four specific aims: Aim 1, Establish, implement and validate bioinformatics tools and databases to support microarray design and updates; Aim 2, Create specialized arrays for detection and speciation of select viral agents and influenza viruses; Aim 3, Establish array protocols for use with clinical materials; and Aim 4, Implement assays in public health laboratories in the New York State Department of Health, the Centers for Disease Control, Hong Kong University, the Robert Koch Institute, and the Public Health Agency of Canada. Features that will enhance the probability of programmatic success include: (1) expertise of applicants in clinical microbiology, bioinformatics, and molecular diagnostics; (2) a sensitive and stable microarray platform; (3) access to proprietary databases of select agent and influenza virus sequences; (4) a comprehensive inventory of extracts from infected cultured cells, naturally and experimentally infected animals, and human victims of infection with select viral agents or influenza viruses; (5) partnership in a dedicated international surveillance network wherein clinical samples can be shared for assay optimization, validation, and implementation to support global public health; and (6) commercial partners with expertise in manufacture, licensure, distribution of diagnostic reagents.

描述（由申请人提供）：该计划的目的是为公共卫生实验室，基于医院的临床实验室和护理点使用的稳定且敏感的病毒微阵列测定法，以使某些NIAID优先药物对感染的诊断差异化，这些药物可能会导致可能导致因感染而导致的症状和症状，这些药物可能会导致症状和症状。我们提出了四个具体目标：AIM 1，建立，实施和验证生物信息学工具和数据库，以支持微阵列设计和更新； AIM 2，创建专门的阵列，用于检测和形态的精选病毒剂和流感病毒； AIM 3，建立用于临床材料的阵列协议； AIM 4，在纽约州卫生部，疾病控制中心，香港大学，罗伯特·科赫研究所和加拿大公共卫生局的公共卫生实验室实施测定法。将提高程序成功概率的功能包括：（1）临床微生物学，生物信息学和分子诊断方面申请人的专业知识； （2）敏感稳定的微阵列平台； （3）访问精选药物和流感病毒序列的专有数据库； （4）自然和实验感染动物的感染细胞中的提取物的全面清单，以及被精选病毒剂或流感病毒感染的人类受害者； （5）在专门的国际监视网络中合作，可以共享临床样本以进行测定优化，验证和实施以支持全球公共卫生； （6）具有生产，许可，诊断试剂分布的专业知识的商业合作伙伴。